IMMP
Immutep LTD ADR

8,801
Loading...
Loading...
News
all
press releases
Immutep's Head & Neck Cancer Therapy Excels
Immutep Ltd (AU:IMM) has released an update. Immutep Ltd has been selected to present its late-breaking abstract at the ESMO Congress 2024, detaili...
TipRanks Financial Blog·1y ago
News Placeholder
More News
News Placeholder
Immutep Ltd (PRRUF) Gets a Buy from Canaccord Genuity
In a report released on August 16, Elyse Shapiro from Canaccord Genuity maintained a Buy rating on Immutep Ltd (PRRUF Research Report), with a pr...
TipRanks Financial Blog·1y ago
News Placeholder
Immutep Readies Phase III Lung Cancer Trial
Immutep Ltd (AU:IMM) has released an update. Immutep Ltd has received positive feedback from the FDA for their upcoming Phase III trial, TACTI-004...
TipRanks Financial Blog·1y ago
News Placeholder
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and Immutep (IMMP)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Roche Holding AG (RHHVF Research Report) and Immutep (IMMP Re...
TipRanks Financial Blog·1y ago
News Placeholder
Australia Based Cancer Focused Immutep's Lead Cancer Drug Shows 'Meaningful Response' In Untreated Head & Neck Cancer, Stock Soars
Immutep announces results from Cohort B of the TACTI-003 Phase 2b trial. The combination of eftilagimod alfa and Merck's Keytruda shows a 35.5% ORR and 58.1% DCR in PD-L1 negative head and neck...
Benzinga·1y ago
News Placeholder
Immutep Limited (NASDAQ:IMMP) Short Interest Up 5.6% in March
Immutep Limited (NASDAQ:IMMP - Get Free Report) was the recipient of a large increase in short interest in March. As of March 15th, there was short interest totalling 1,140,000 shares, an increase...
Zolmax·2y ago
News Placeholder
Immutep (NASDAQ:IMMP) Stock Crosses Above 50-Day Moving Average of $2.35
Immutep Limited (NASDAQ:IMMP - Get Free Report) crossed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $2.35 and traded as high as $2.47. Immutep...
Zolmax·2y ago
News Placeholder
Immutep announces first clinical data from 90mg dosing of efti
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·2y ago
News Placeholder
Immutep Announces First Clinical Data from 90mg Dosing of Efti
Data from the safety lead-in of the AIPAC-003 trial shows 90mg efti in combination with paclitaxel is safe and well toleratedEncouraging initial efficacy in six metastatic breast cancer patients, who...
Globe Newswire·2y ago
News Placeholder
Immutep Limited (NASDAQ:IMMP) Short Interest Up 53.4% in January
Immutep Limited (NASDAQ:IMMP Get Free Report) was the recipient of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling...
Zolmax·2y ago

Latest IMMP News

View

Advertisement|Remove ads.

Advertisement|Remove ads.